An Open-label Multi-center Single Agent Panobinostat Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Panobinostat Study and Are Judged by the Investigator to Benefit From Continued Single Agent Panobinostat Treatment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Panobinostat (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Feb 2017 Planned End Date changed from 1 Oct 2018 to 9 Nov 2018.
- 07 Feb 2017 Planned primary completion date changed from 1 Oct 2018 to 9 Nov 2018.
- 07 Jan 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.